» Articles » PMID: 17304887

Efficacy and Safety of Ciclesonide, 200 Microg Once Daily, for the Treatment of Perennial Allergic Rhinitis

Overview
Date 2007 Feb 20
PMID 17304887
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ciclesonide is an intranasal corticosteroid approved for the treatment of allergic rhinitis (AR).

Objective: To evaluate the efficacy, safety, and quality-of-life benefits of intranasal ciclesonide, 200 microg once daily, for the treatment of perennial AR (PAR).

Methods: In this multicenter, randomized, double-blind, placebo-controlled study, adults and adolescents with at least a 2-year history of PAR received intranasal ciclesonide, 200 microg, or placebo once daily for 6 weeks. Patient-evaluated total nasal symptom scores (TNSSs), physician-assessed overall nasal signs and symptoms severity scores, and Rhinoconjunctivitis Quality of Life Questionnaire scores were evaluated.

Results: Patient baseline characteristics were similar in the ciclesonide (n = 238) and placebo (n = 233) groups and were consistent with moderate PAR severity. Ciclesonide therapy significantly reduced average morning and evening reflective TNSSs compared with placebo (P < .001) and significantly reduced average morning and evening instantaneous TNSSs (P = .001) over 6 weeks of treatment. At the end point, a greater decrease from baseline was observed in physician-assessed overall nasal signs and symptoms severity for the ciclesonide group compared with the placebo group (P = .051). An appreciable improvement in combined Rhinoconjunctivitis Quality of Life Questionnaire scores at the end point was also observed in the ciclesonide group (P = .01 vs placebo). The frequency of adverse events was similar between treatment groups.

Conclusions: In this study, intranasal ciclesonide treatment was associated with significant reductions in nasal symptoms and appreciable improvements in health-related quality of life in adult and adolescent patients with PAR. Ciclesonide was well tolerated, with a safety profile comparable with that of placebo.

Citing Articles

Efficacy of and (NVP-1703) in Children With Allergic Rhinitis: A Randomized Controlled Trial.

Jeong K, Jang S, Jeon S, Seo H, Kang S, Han S J Korean Med Sci. 2024; 39(40):e266.

PMID: 39435516 PMC: 11496560. DOI: 10.3346/jkms.2024.39.e266.


Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis.

Soe K, Krikeerati T, Pheerapanyawaranun C, Niyomnaitham S, Phinyo P, Thongngarm T Front Pharmacol. 2023; 14:1184552.

PMID: 37288109 PMC: 10242043. DOI: 10.3389/fphar.2023.1184552.


The efficacy and safety of ciclesonide for the treatment of perennial allergic rhinitis: a systematic review and meta-analysis.

Yang Q, Wang F, Li B, Wu W, Xie D, He L Braz J Otorhinolaryngol. 2018; 85(3):371-378.

PMID: 30522830 PMC: 9442893. DOI: 10.1016/j.bjorl.2018.10.008.


The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients.

Keith P, Desrosiers M, Laister T, Schellenberg R, Waserman S Allergy Asthma Clin Immunol. 2012; 8(1):7.

PMID: 22656186 PMC: 3490734. DOI: 10.1186/1710-1492-8-7.


Intranasal ciclesonide for allergic rhinitis.

Williams B, Smith W, Kette F J Asthma Allergy. 2011; 1:49-54.

PMID: 21436985 PMC: 3121337. DOI: 10.2147/jaa.s3082.